July 24th 2025
The addition of retifanlimab to chemotherapy increased progression-free survival in patients with advanced squamous cell carcinoma of the anal canal.
FDA Grants Breakthrough Designation to Atezolizumab Combo for Advanced HCC
July 19th 2018The FDA has granted a breakthrough therapy designation to atezolizumab (Tecentriq) for use in combination with bevacizumab (Avastin) as a first-line treatment for patients with advanced or metastatic hepatocellular carcinoma (HCC).
Heated Chemo During Resection Shows No Benefit in Advanced CRC
July 13th 2018The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis, according to phase III study results presented at the 2018 ASCO Annual Meeting.
Four-Drug Chemo Combo Significantly Improves Pancreatic Cancer Survival
July 9th 2018In a major advance that set a new standard of care for the treatment of patients with resected pancreatic cancer, a modified FOLFIRINOX regimen (mFOLFIRINOX) dramatically improved survival compared with standard gemcitabine as postoperative therapy.
TAS-102 Prolongs Survival in Patients With Advanced Gastric Cancer
July 6th 2018Patients with heavily pretreated metastatic or advanced gastric cancer who received TAS-102 (trifluridine/tipiracil; Lonsurf) saw a significant overall survival benefit, according to phase III study findings presented at the 2018 World Gastrointestinal Cancer Congress.
BLU-667 Shows Clinical Benefit in Advanced, RET-Altered Solid Tumors
April 20th 2018BLU-667 appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies, according to study findings from a phase I clinical trial presented at the AACR Annual Meeting 2018.
Diets Rich in Nuts Improve Survival Rates in Patients with Colon Cancer
April 5th 2018Patients with stage III colon cancer who ate at least 2 servings of nuts per week had superior disease-free survival (DFS) and overall survival (OS), according to results from the CALGB 8903 study published in the Journal of Clinical Oncology.
FDA Grants Priority Review to Nivolumab/Ipilimumab for Subgroup of Patients With Colorectal Cancer
March 27th 2018The FDA has granted a priority review to the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for the treatment of adult patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.
Clonal Evolution in MSI-H Colorectal Cancer Suggests Repeated Molecular Testing May Be Necessary
February 28th 2018Genetic changes that occur during DNA cloning in people with microsatellite instability-high (MSI-H) colorectal cancer may affect the efficacy of targeted and immunologic therapies. Repeated testing may be necessary to ensure that targeted treatments keep up with the changes in DNA.
Older Patients with Colorectal Cancer Are More Likely to Develop Cardiovascular Disease
February 2nd 2018According to results from an analysis of the Surveillance, Epidemiology, and End Results database of the National Cancer Institute, older adults with colorectal cancer are more likely to develop cardiovascular disease and congestive heart failure.